Eleusis SPAC

CHALLENGE: Unlock the Therapeutic Potential of Psychedelics (1 2 3 eleusis Promising Efficacy Data in Depression Concerns About Practicality The "Last Mile" of Care Delivery ■ Major Depressive Disorder (MDD) is the leading cause of disability worldwide and a major contributor to global disease burden¹ Psilocybin, an investigational psychedelic drug, observed to have rapid, robust, and durable antidepressant effect in third party clinical studies² Encapsulated psilocybin may only be "half-way" to a medicine due to the limitations of oral formulation Psilocybin and other psychedelic drug therapies in development may not be compatible with conventional psychiatric practice or existing frameworks for "in-network" insurance coverage and reimbursement Source: 1) WHO Fact Sheet, 9/13/21 https://www.who.int/news-room/fact-sheets/detail/depression 2) Carhart-Harris, R.L, et al. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402-1411; Compass Pathways Press Release, 11/9/2021; https://compasspathways.com/positive-topline-results/); Davis, A. K., et al. (2020). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder. JAMA Psychiatry. 3

View entire presentation